In one study, an EGFR-mutated NSCLC xenograft model was treated with erlotinib until resistance was detected, which revealed decreased VEGF levels after initial erlotinib treatment and increased VEGF levels after the development of erlotinib resistance [27]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.